Yazar "Taskin O." seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Effect of etidronate on urinary Calcium/Creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study(1999) Kucuk S.; Gokdeniz R.; Atmaca R.; Uryan I.; Buhur A.; Taskin O.There are both histomorphometric and nonhistomorphometric studies confirming that etidronate reduces bone resorption. In this study, we have examined urinary Calcium/Creatinine ratio (uCa/Cr) as a biochemical marker of bone turnover to show the effectiveness of etidronate and whether it could be used as a follow-up parameter of treatment. Eighty-one postmenopausal women aged 40 to 65 included into the study to investigate the effects of etidronate on uCa/Cr in a prospective, randomised, placebo controlled clinical trial. All necessary criteria matched 81 women were divided into 3 groups at random, each group consisted of 27 patients. Prior to treatment, uCa/Cr was calculated from all subjects 3 hours after drinking 1 liter of water in the morning. Twenty seven (33.3%) women were randomised to oral doses of etidronate (400 mg/day for two weeks followed by drug free period of 10 weeks), twenty seven women to etidronate (400 mg/day for two weeks) plus calcium (1000 mg/day) for the following 10 weeks and twenty seven women to placebo (Fe, 50 mg/day) for 12 weeks. After 12 weeks of treatment, uCa/Cr declined significantly in the etidronate group from 0.118±0.064 to 0.053±0.021, in etidronate+calcium group from 0.08±0.03 to 0.06±0.015 ((p=0.004) and (p=0.005), respectively). In the placebo group no significant change was observed (p=0.03). In conclusion, etidronate is effective in postmenopausal women and the effectiveness of treatment may be followed up by measuring uCa/Cr which is a simple and cheap parameter of determining the effectiveness of etidronate in prevention of osteoporosis. However, since there are contradictory findings concerning uCa/Cr exist, larger clinical and prospective studies should be carried out.Öğe Öğe In vitro comparison of four tocolytic agents, alone and in combination(1994) Saade G.R.; Taskin O.; Belfort M.A.; Erturan B.; Moise K.J.; Jr.Objective: To compare the tocolytic effects or magnesium sulfate, ritodrine, terbutaline, and nifedipine on human myometrial strips. Methods: Myometrial strips were suspended in organ chambers for isotonic measurements and contracted with KCl. Strips from nonpregnant patients were used to obtain concentration-response curves. Myometrial strips from pregnant uteri were then exposed to the molar concentrations causing 50% relaxation in the nonpregnant tissues. Results: In strips from nonpregnant patients, nifedipine was found to be the most potent tocolytic. Using strips from nonlaboring patients, nifedipine caused relaxation similar to ritodrine, and both were more effective than magnesium sulfate or terbutaline. Combinations were more effective than single agents. These agents were found to be equally less effective in myometrial strips from laboring patients. Conclusions: Nifedipine, alone or in combination, relaxes myometrial strips more effectively than the other agents studied. Myometrial strips from laboring patients are more resistant to inhibition, with none of the agents being superior. © 1994 by The American College of Obstetricians and Gynecologists.Öğe Insulin-like growth factor binding proteins in peritoneal fluid of women with minimal and mild endometriosis(Oxford University Press, 1996) Taskin O.; Giudice L.; Mangal R.; Dunn R.C.; Dsupin B.A.; Poindexter A.N.; Wiehle R.D.This prospective cohort study was carried out in a university-based infertility clinic to determine the profile of insulin-like growth factor binding proteins (IGFBPs) in patients with mild endometriosis and no obvious mechanical factor contributing to infertility. A total of 26 patients with minimal and mild endometriosis and 10 controls contributed peritoneal fluid at surgery. The variety, expression and levels of IGFBPs were determined by radioimmunoassay and Western ligand blots (WLBs) with quantitation by laser densitometer. A 27 kDa species was significantly lower and a 31 kDa species tended to be lower in patients with endometriosis as determined by quantitative laser densitometer. The levels of IGFBP-3 detected by radioimmunoassay and by WLB were correlated in the control group and in-the patients with endometriosis in the follicular phase but not in patients with endometriosis in the luteal phase. The level of 27 kDa species seen on WLBs did not appear to correspond to IGFBP-1 determined by radioimmunoassay and IGFBP-3 levels in luteal phase endometriosis patients also departed from values determined by radioimmunoassay. These discrepancies suggest a complex system to control levels of IGF in the peritoneum involving multiple binding proteins and proteases. The IGFBPs of patients with endometriosis may contribute to reproductive dysfunction and be able to serve as markers.Öğe Prevention and treatment of ovarian cysts with oral contraceptives: A prospective randomized study(Mary Ann Liebert Inc., 1996) Taskin O.; Young D.C.; Mangal R.; Aruh I.To determine if treatment with low-dose combination oral contraceptives hastened resolution of ovarian cysts or prevented their occurrence, we conducted a prospective randomized study of 45 women with ovarian cysts and 50 women without ovarian cysts and divided the patients into four groups. Group A patients (n = 25) had no cysts and received oral contraceptives, group B patients (n = 25) had no cysts and were expectantly managed, group C patients (n = 25) had cysts and received oral contraceptives, and group D patients (n = 20) had cysts and were observed. All patients were followed with transvaginal ultrasound examinations every 4 weeks for three cycles, with cyst dimensions and ovarian volumes recorded. There were no statistically significant changes in the size of the cysts or ovarian volumes between groups who received oral contraceptives and groups who received expectant management (p > 0.05) Prophylactic treatment with the oral contraceptive did produce a statistically significant reduction in the incidence of ovarian cyst formation. Cyclic low-dose oral contraceptives had no effect on resolution of ovarian cysts but did seem to protect against cyst formation in short-term use.Öğe Therapeutic effect of diasmin-hesperidin in primary dysmenorrhea(1997) Kafkasli A.; Buhur A.; Burak F.; Taskin O.Objective: To evaluate the effect of Flavinoid fraction; 450 mg Diasmin + 50 mg Hesperidin (DH), a venotrophic drug, in the treatment of the primary dysmenorrhea. Study Design: Thirty women, presenting with moderate (6 of 30, 20%) or severe (24 of 30, 80%) primary dysmenorrhea, were randomly divided into 2 groups. Each group received either DH tid or placebo for three months immediately after the onset of the menstrual flow and then each group was switched to the other regimen for the following three months. Ten point visual analogue scale was used to measure the pain of the patients. Statistical analysis was carried out by using student's t test, and chi square-test. Results: Pain scores were similiar in the placebo and the DH treated groups before treatment (7.5 ± 0.7 and 8.1 ± 0.2 respectively). Pain scores began to decrease one-hour following the DH administration and reduced to the lowest point at the third hour (from 5.5 ± 0.9 to 3.4 ± 0.9, p < 0.05). Satisfactory pain relief was detected in 90% of the patients. Meanwhile, pain scores in the placebo group did not change (7.8 ± 0.1 versus 7.6 ± 0.2, p > 0.05). The severity of the pain returned to pretreatment levels when the patients were switched to placebo. Conclusion: DH may be an effective drug for the treatment of primary dysmenorrhea in patients who can not use nonsteroidal anti-inflammatory drugs.
